Ranluspec is a biosimilar drug with the active ingredient ranibizumab, which is highly similar to the reference product Lucentis[1]. The CHMP issued a positive opinion on 11 December 2025 recommending the granting of a marketing authorisation for Ranluspec for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema following retinal vein occlusion (BRVO or CRVO) and chorioretinal neovascularisation[1]. Ranluspec is available as a 10 mg/ml solution for injection and its mechanism of action is to inhibit VEGF-A, thereby reducing new vessel formation and fluid leakage in the retina[1]. Lupin Europe GmbH is the applicant for registration[1]. The ATC code for ranibizumab is S01LA04[1]. The EPAR states that ranibizumab is a monoclonal antibody fragment that modulates angiogenesis by blocking VEGF-A[1]. The CHMP opinion is positive (Opinion) and recommends granting marketing authorisation for the indications listed[1].